cover
Article Per Year (5 Year)
All
Home Page
OAI Link
Editorial Team
Contact
Reviewer
Google Scholar
Contact Name
Andri Putra Kesmawan
Contact Email
journal@idpublishing.org
Phone
+6281990251989
Journal Mail Official
journal@idpublishing.org
Editorial Address
Perumahan Sidorejo, Jl. Sidorejo Gg. Sadewa No.D3, Sonopakis Kidul, Ngestiharjo, Kapanewon Kasihan, Kabupaten Bantul, Daerah Istimewa Yogyakarta 55184
Location
Kab. bantul,
Daerah istimewa yogyakarta
INDONESIA
Sciences and Clinical Pharmacy Research Journal
Published by Indonesian Journal Publisher
ISSN : -     EISSN : 30474493     DOI : https://doi.org/10.47134/scpr
Core Subject : Health,
Medicine & Pharmacology
Sciences and Clinical Pharmacy Research Journal is dedicated to the exploration of Pharmaceutical Sciences and Community and Clinical Pharmacy. In the realm of pharmaceutical sciences, the journal welcomes research articles spanning Pharmaceutical Biology and Pharmacognosy, Pharmaceutical Chemistry, pharmaceutics, Pharmacology and Toxicology, as well as Biotechnology. In the domain of Community and Clinical Pharmacy, the journal encompasses discussions on Hospital Pharmacy, Clinical Pharmacy, Pharmacy Management, and Social Pharmacy.
Arjuna Subject : Pharmacology, Toxicology and Pharmaceutics - Ilmu Farmasi
Articles 42 Documents
 1   2   3   4   5 
Re-evaluating Albendazole-Based Preventive Chemotherapy for Soil-Transmitted Helminths in Indonesia: A Narrative Review on Efficacy, Challenges, and Future Strategies Lala Gunasari; Dian Nurmansyah; Dessy Triana
Sciences and Clinical Pharmacy Research Journal Vol. 3 No. 1 (2026): April
Publisher : Indonesian Journal Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.47134/scpr.v3i1.5601

Abstract

This narrative review seeks to critically analyze the efficacy of albendazole, the cornerstone anthelmintic of the program. Relevant literature (2020-2025) was identified through a systematic search of the ScienceDirect and Google Scholar databases. While evidence confirms albendazole's effectiveness, with cure rates up to 93%, its performance is inconsistent and influenced by a confluence of factors. A critical constraint identified is the absence of robust, large-scale national surveillance data on STH prevalence and drug efficacy, hindering a comprehensive assessment of albendazole's performance within the program. The persistent burden of STH underscores a gap between program implementation and its intended public health impact. While albendazole remains essential, its variable efficacy and operational barriers necessitate a critical reassessment of the current strategy.
Analysis of Potential Drug–Drug Interactions in Pediatric HIV/AIDS Patients with Comorbidities at Dr. M. Djamil General Hospital Padang Based on Reliability and Risk Ratings Elsa Marsellinda
Sciences and Clinical Pharmacy Research Journal Vol. 3 No. 2 (2026): July
Publisher : Indonesian Journal Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.47134/scpr.v3i2.5952

Abstract

To analyze potential drug-drug interactions among pediatric HIV/AIDS patients with comorbidities at RSUP Dr. M. Djamil Padang based on reliability and risk ratings. A descriptive retrospective study was conducted using medical records of pediatric HIV/AIDS patients treated in 2024. Potential DDIs were identified using the Lexicomp Drug Interactions Database. A total of 53 patients were included. Most patients were male (50.94%) and in the child age group (49.06%). A total of 107 potential drug-drug interactions were identified. Most interactions were classified as Good based on reliability rating (77.57%) and Category C (Monitor Therapy) based on risk rating (80.37%). No Category X interactions were found. Potential drug-drug interactions were common among pediatric HIV/AIDS patients with comorbidities, with most interactions requiring therapeutic monitoring.

Page 5 of 5 | Total Record : 42

 1   2   3   4   5 

Filter by Year

2024 2026


Reset
Filter By Issues
All Issue Vol. 3 No. 2 (2026): July Vol. 3 No. 1 (2026): April Vol. 2 No. 4 (2026): January Vol. 2 No. 3 (2025): October Vol. 2 No. 2 (2025): July Vol. 1 No. 4 (2025): January Vol. 1 No. 3 (2024): October Vol. 1 No. 2 (2024): July Vol. 1 No. 1 (2024): April